Haemophilia A: from mutation analysis to new therapies
- 1 June 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Genetics
- Vol. 6 (6), 488-501
- https://doi.org/10.1038/nrg1617
Abstract
Haemophilia is caused by hundreds of different mutations and manifests itself in clinical conditions of varying severity. Despite being inherited in monogenic form, the clinical features of haemophilia can be influenced by other genetic factors, thereby confounding the boundary between monogenic and multifactorial disease. Unlike sufferers of other genetic diseases, haemophiliacs can be treated successfully by intravenous substitution of coagulation factors. Haemophilia is also the most attractive model for developing gene-therapy protocols, as the normal life expectancy of haemophiliacs allows the side effects of gene therapy, as well as its efficiency, to be monitored over long periods.Keywords
This publication has 100 references indexed in Scilit:
- Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complexNature Genetics, 2003
- Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia ASeminars in Thrombosis and Hemostasis, 2000
- Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctionsHuman Molecular Genetics, 1995
- Molecular etiology of factor VIII deficiency in hemophilia AHuman Mutation, 1995
- Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cellsHuman Molecular Genetics, 1994
- Sequence of the Murine Factor VIII cDNAGenomics, 1993
- Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNAGenomics, 1990
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- Characterization of the human factor VIII geneNature, 1984
- The history of haemophilia.Journal of Clinical Pathology, 1976